News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
196,539 Results
Type
Article (19506)
Company Profile (110)
Press Release (176923)
Section
Business (63884)
Career Advice (815)
Deals (9044)
Drug Delivery (71)
Drug Development (18776)
Employer Resources (137)
FDA (3340)
Job Trends (5994)
News (95251)
Policy (7061)
Tag
Academia (1486)
Alliances (17272)
Alzheimer's disease (510)
Antibody-drug conjugate (ADC) (47)
Approvals (3316)
Artificial intelligence (77)
Bankruptcy (47)
Best Places to Work (4888)
Biotechnology (68)
Breast cancer (56)
Cancer (401)
Cardiovascular disease (42)
Career advice (718)
CAR-T (41)
Cell therapy (103)
Clinical research (14007)
Collaboration (217)
Compensation (43)
COVID-19 (951)
C-suite (62)
Data (412)
Diabetes (48)
Diagnostics (2320)
Earnings (14330)
Employer resources (117)
Events (29125)
Executive appointments (191)
FDA (3503)
Funding (188)
Gene therapy (74)
GLP-1 (282)
Government (1302)
Healthcare (4907)
Infectious disease (990)
Inflammatory bowel disease (46)
Interviews (113)
IPO (3616)
Job creations (1301)
Job search strategy (634)
Layoffs (148)
Legal (1176)
Lung cancer (66)
Manufacturing (91)
Medical device (2595)
Medtech (2599)
Mergers & acquisitions (5532)
Metabolic disorders (160)
Neuroscience (635)
NextGen Class of 2024 (2104)
Non-profit (1682)
Northern California (515)
Obesity (107)
Opinion (99)
People (26662)
Phase I (4126)
Phase II (5804)
Phase III (5591)
Pipeline (125)
Postmarket research (559)
Preclinical (2360)
Press Release (61)
Radiopharmaceuticals (59)
Rare diseases (80)
Real estate (2507)
Recruiting (53)
Regulatory (4964)
Research institute (1259)
Resumes & cover letters (106)
Southern California (341)
Startups (2000)
United States (4370)
Vaccines (166)
Weight loss (84)
Date
Today (13)
Last 7 days (203)
Last 30 days (741)
Last 365 days (11477)
2024 (11210)
2023 (13016)
2022 (15610)
2021 (17741)
2020 (16359)
2019 (15102)
2018 (10900)
2017 (10361)
2016 (10242)
2015 (10945)
2014 (8075)
2013 (7008)
2012 (7422)
2011 (7598)
2010 (7058)
Location
Africa (327)
Arizona (54)
Asia (11116)
Australia (1939)
California (1037)
Canada (422)
China (86)
Colorado (59)
Delaware (49)
Europe (28494)
Florida (142)
Illinois (98)
Indiana (97)
Maryland (139)
Massachusetts (888)
Michigan (68)
Minnesota (90)
New Jersey (344)
New York (403)
North Carolina (246)
Northern California (515)
Ohio (47)
Pennsylvania (179)
South America (394)
Southern California (341)
Texas (146)
Washington State (91)
196,539 Results for "sage science".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Editorial
Embattled Sage Dealt Deeper Blow With Huntington’s Failure
Sage Therapeutics discontinued development of its lead candidate dalzanemdor after a third clinical failure, leading analysts to question the biotech’s future profitability.
November 25, 2024
·
4 min read
·
Heather McKenzie
Huntington’s disease
Sage Scraps Huntington’s Hopeful After Disappointing Phase II Data
After previously failing studies in Parkinson’s and Alzheimer’s, dalzanemdor’s latest stumble in Huntington’s disease has pushed Sage Therapeutics to pull the plug on the NMDA receptor modulator.
November 20, 2024
·
2 min read
·
Tristan Manalac
Podcast
Trodelvy’s Bladder Cancer Withdrawal, Sage Therapeutics Layoffs, Sanofi’s Radiopharma Investment, More
Yet another therapy with FDA accelerated approval suffers a setback; Sage’s tough year continues; Sanofi drops $326 million in radiopharma while selling its consumer health unit; Novo Nordisk’s positive Rybelsus results in cardiovascular disease; and more.
October 23, 2024
·
1 min read
·
Heather McKenzie
Earnings
Sage Touts Q3 Zurzuvae Revenue Growth, Will Not Seek MDD Indication
On its third-quarter earnings call Tuesday, Sage highlighted the launch of its Biogen-partnered postpartum depression drug Zurzuvae but said it will stop pursuing approval for major depressive disorder, which the FDA previously denied.
October 30, 2024
·
2 min read
·
Heather McKenzie
Layoffs
Sage Therapeutics Will Lay Off 33% of Employees, Including Over Half of R&D
As part of a strategic reorganization intended in part to support the ongoing launch of its postpartum depression drug, Sage Therapeutics is cutting more than 165 employees.
October 17, 2024
·
2 min read
·
Angela Gabriel
Alzheimer’s disease
Sage Suffers Third Neuro Stumble in Six Months With Disappointing Mid-Stage Alzheimer’s Readout
Sage has decided to discontinue the development of dalzanemdor in Alzheimer’s disease. A study of the candidate in Huntington’s is ongoing, with early data expected later this year.
October 8, 2024
·
2 min read
·
Tristan Manalac
Clinical research
Biogen, Sage Scrap Essential Tremor Study After Phase II Failure
Biogen and Sage Therapeutics’ investigational neuroactive steroid did not significantly improve upper limb tremors in patients with essential tremor, the companies announced Wednesday.
July 24, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease
November 20, 2024
·
4 min read
Drug Development
Sage’s Dalzanemdor Shows Effect in Huntington’s Study, Analysts Say Results ‘Underwhelming’
While Sage Therapeutics’ drug candidate showed a slight difference compared to placebo in a mid-stage Huntington’s disease trial, William Blair analysts in a Tuesday note to investors said they “remain cautious” on dalzanemdor and “do not view the small numerical changes as definitive.”
June 11, 2024
·
2 min read
·
Tyler Patchen
Press Releases
Sage Therapeutics Announces Discontinuation of the Collaboration with Biogen on the SAGE-324 Program
September 27, 2024
·
6 min read
1 of 19,654
Next
